Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
about
Stress triggers coronary mast cells leading to cardiac eventsRole of Corticotropin-releasing Factor in Gastrointestinal Permeability.Corticotrophin-Releasing Factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes.Stress-induced differences in primary and secondary resistance against bacterial sepsis corresponds with diverse corticotropin releasing hormone receptor expression by pulmonary CD11c+ MHC II+ and CD11c- MHC II+ APCs.Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptorsUrocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying.Multi-facets of Corticotropin-releasing Factor in Modulating Inflammation and Angiogenesis.Effect of natsudaidain isolated from Citrus plants on TNF-alpha and cyclooxygenase-2 expression in RBL-2H3 cells.Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors.Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implicationsThe joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome.Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.Urocortins and CRF receptor type 2 variants in the male rat colon: gene expression and regulation by endotoxin and anti-inflammatory effectCorticotropin-releasing factor receptor 2 mediates sex-specific cellular stress responsesVIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.Tracing the dynamics of gene transcripts after organismal death.Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract.Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection.Activation of corticotropin-releasing factor receptor 2 inhibits the growth of human small cell lung carcinoma cells.Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells.Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.Pro-inflammatory M1 macrophages promote Osteogenesis by mesenchymal stem cells via the COX-2-prostaglandin E2 pathway.Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.Activation of corticotropin-releasing factor receptor 1 aggravates dextran sodium sulphate-induced colitis in mice by promoting M1 macrophage polarization.Involvement of Corticotropin-Releasing Factor and Receptors in Immune Cells in Irritable Bowel Syndrome.Expression of Inflammatory and Neurogenic Mediators in Adenomyosis.Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide.
P2860
Q27022598-FCA15DC6-FF56-4F88-934E-CFB613F7FE5EQ30421083-5FACB0A2-BD9D-4CA2-8AAF-1F6DA0DCF6EBQ33623899-B2162C5F-AE1A-4CA6-BB82-6A47F787BF19Q33768488-E728D0D3-71F9-4AC8-91B5-4C897AD343DEQ33958801-67C82D57-885E-41AA-AD55-8775DC4230DCQ34208577-2416D477-25C3-41BA-B970-DF90EB3486CAQ34231605-3C4E11C3-B55B-4060-8B54-5A3987A1FA62Q34240005-7F392A91-F3AA-497F-A35F-6C22A7FA4733Q34882241-D5896735-3822-4DAE-87AA-D794008D04FAQ34916375-3C447205-8D8B-4979-B224-E1025D97066EQ35141280-0CD6C2AD-8DFE-4C33-AC45-ED1B3F963AD0Q35809342-283AFAB1-7F7D-4381-B760-DD0D4BDAADD4Q35838055-AFEECE18-EA52-4A55-975A-1A4D1E08ADC6Q35894035-97D12B02-05C0-42BE-9F57-588CB84BCFC2Q36698796-06DFDDEC-9D6A-4C67-A986-D1B919BBB4D2Q37100274-13A8214C-BA9D-4693-B69B-985A2B42E33EQ37447842-8E6BDDF9-83F2-42DD-B4E2-44753923B5CAQ37637116-B901A78F-C3D5-4E0F-9144-77AE7D2D1B92Q37863053-A9F4203A-86F8-4576-ACF3-0CFD6D6D172DQ37871872-AB14D332-9EEA-4095-B660-9A4F80E73899Q38954134-90DCDDFA-E9D3-493E-924E-F2CA42C16D3DQ39766058-8913F66C-840B-411B-B8CB-097AA7FCCCC4Q41815710-D6CAF297-5494-493D-9023-251D0FE15908Q42589673-8C3BC204-B93D-4D88-B13A-5D34C61EAC9CQ46183672-04D9D68C-FD1C-4AEF-90A4-9F3C5D5619FEQ48120538-5F74FBCB-3295-4BD8-87D6-CF44E19922E6Q50077577-8FD9835F-44D3-4497-AA1B-97E2E239D727Q50351674-78CFF05A-9B49-44A4-A6D1-679FEBA66B91Q50497050-C741C165-0D3A-4A1C-8CA3-D5365F663DD0Q54385451-27743FE2-49D0-471A-897F-7FE0197E5904
P2860
Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Corticotropin releasing factor ...... a induction of COX-2 and PGE2.
@en
type
label
Corticotropin releasing factor ...... a induction of COX-2 and PGE2.
@en
prefLabel
Corticotropin releasing factor ...... a induction of COX-2 and PGE2.
@en
P2093
P356
P1476
Corticotropin releasing factor ...... a induction of COX-2 and PGE2.
@en
P2093
Achille Gravanis
Andrew N Margioris
Ariadne Androulidaki
Erini Dermitzaki
P2860
P304
P356
10.1002/JCP.20900
P577
2007-03-01T00:00:00Z